Transdur (sufentanil) / Durect - LARVOL DELTA

[VIRTUAL] Postoperative Paraplegia After Transdural Spinal Cord Herniation Repair (ASA 2020) - "Patient returned to OR for removal of laminoplasty and expansion of duraplasty with lumbar drain placement. Patient outcome of bilateral LE paralysis with decreased sensation to light touch below T6 dermatome."

Anesthesia

Durect Corporation announces fourth quarter 2012 financial results and update of programs (PRNewswire) - "'Communications with Pfizer indicate that they intend to meet with the FDA as planned in late March to discuss their proposed resubmission plan for REMOXY®'...We have multiple programs that may potentially be licensed over the next 12-18 months. These include POSIDUR, TRANSDUR-Sufentanil, ELADUR,..."

Anticipated FDA event • Anticipated licensing / partnership • Pain

Durect Corporation announces first quarter 2013 financial results and update of programs (PRNewswire) - "We note the recent additional patent issuance extending coverage of REMOXY in the U.S. to at least 2031...DURECT has two transdermal products...TRANSDUR®-Sufentanil...ELADUR®...We are in discussions with potential partners regarding licensing development and commercialization rights to these two transdermal programs for which we hold worldwide rights."

Anticipated licensing / partnership • Anticipated patent expiry • Pain